Implant Sciences' QS-B220 Explosives Trace Detector Selected by Fine Arts Shipper for Air Cargo Screening
WILMINGTON, Mass., Feb.19, 2014 /PRNewswire/ -- Implant Sciences Corporation (OTCQB:IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today that San Francisco-based Lawrence Fine Art Services has purchased the QS-B220™ desktop explosives trace detector (ETD) for air cargo screening.
A high-end transportation, crating, storage and installation company for art and antiques, Lawrence Fine Art Services has been providing expert fine arts services to museums, galleries, and corporate and private collectors since 1984. As a Certified Cargo Screening Facility (CCSF), Lawrence Fine Art Services is required to use TSA qualified systems when screening air cargo packages for explosives before they are loaded onto airplanes.
"We've been looking to upgrade our legacy security equipment with new, state-of-the art technologies. When evaluating TSA-qualified ETDs, we found that the QS-B220 offers high performance and a low total cost of ownership. We particularly like the remote diagnostics functionality, which enables us to get immediate diagnostic and system support from Implant Sciences' service team. We expect that remote diagnostics can help us drastically minimize downtime and get the most use and value out of the ETD," stated President of Lawrence Fine Art Services, Dick Drossler.
"As we continue to gain new customers, who were previously using our competitors' systems, one of the messages coming through loud and clear is their need for better service and support. We believe that customers are choosing Implant Sciences because we are a company that is dedicated to cultivating long-term customer relationships built on responsive customer service and support offerings," commented Implant Sciences' Vice President of Sales and Marketing, Dr. Darryl Jones. "Our unique remote diagnostics capability is just one of the ways we are meeting customer needs and demands."
About the QS-B220 Desktop Explosives Trace Detector
The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.
About Implant Sciences
Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to have product approval from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA qualification for air cargo screening, the Company's QS-B220 has also received STAC certification, a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act), and the GSN 2013 Homeland Security Award for "Best Explosives Detection Solution". For further details on the Company and its products, please visit the Company's website at http://www.implantsciences.com.
Safe Harbor Statement
This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change, and our success will depend on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.
Implant Sciences Corporation
Glenn Bolduc, CEO
SOURCE Implant Sciences Corporation